Loading clinical trials...
Loading clinical trials...
This is a Phase I, open-label, dose escalation study of UCART123 administered intravenously to patients with newly diagnosed CD123 positive adverse genetic risk acute myeloid leukaemia (AML) defined i...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Cellectis S.A.
NCT06928909 · Acute Myeloid Leukaemia
NCT07148180 · Acute Myeloid Leukaemia (AML), Leukemia, and more
NCT05534620 · Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), and more
NCT06434662 · Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
NCT06345365 · Acute Myeloid Leukaemia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions